Office Action Predictor
Last updated: April 15, 2026
Application No. 18/571,216

CRYSTAL FORM OF PYRIMIDINE DERIVATIVE AND PREPARATION METHOD THEREFOR

Non-Final OA §112
Filed
Dec 16, 2023
Examiner
BARSKY, JARED
Art Unit
1628
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Zhejiang Hisun Pharmaceutical Co., LTD.
OA Round
1 (Non-Final)
50%
Grant Probability
Moderate
1-2
OA Rounds
2y 7m
To Grant
62%
With Interview

Examiner Intelligence

Grants 50% of resolved cases
50%
Career Allow Rate
461 granted / 915 resolved
-9.6% vs TC avg
Moderate +12% lift
Without
With
+11.5%
Interview Lift
resolved cases with interview
Typical timeline
2y 7m
Avg Prosecution
88 currently pending
Career history
1003
Total Applications
across all art units

Statute-Specific Performance

§101
1.3%
-38.7% vs TC avg
§103
48.6%
+8.6% vs TC avg
§102
9.8%
-30.2% vs TC avg
§112
16.0%
-24.0% vs TC avg
Black line = Tech Center average estimate • Based on career data from 915 resolved cases

Office Action

§112
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Claim of Foreign Priority Applicant’s claim of foreign priority to CN202110696953.6 and Certified Copy of Foreign propriety documents are acknowledged. To perfect such priority, Applicant is required to provide an English language translation of the foreign priority documents. Objections to the Drawings The Drawings are objected to for being illegible/blurry. Clear versions are requested. Status of the Claims Claims 1-4, 21, and 22 are pending and examined. Allowable Subject Matter Claims 1 is allowed. Requirement for Information The examiner makes Request for Information pursuant to M.P.E.P. § 704.11(b). The examiner notes that the Specification and claim 4 provide 5 separate methods for arriving at a single polymorph. The examiner requests confirmation that each of the processes described in claim 4 when performed independently will yield a claimed polymorph of crystal form A; and The examiner requests confirmation that the methods and products described in the following U.S. Pat. Nos. assigned to Applicant do not include and/or yield a polymorph of crystal form A. Those patent nos. are: 10,654,836; 11,001,572; 11,827625; and 12,358,898. The examiner makes this same request with respect to WO/2017/198221 referred to in the instant Specification at paragraphs 6 and 7 as yielding only amorphous solid forms. The examiner did not identify prior art relevant to be applied to the claimed polymorph with the exception of the list documents set forth above. The examiner will weigh allowability based upon the factual statements provided by Applicant in response to this Request. The status of the claims may change depending upon the response to this Request. Claim Rejections - 35 USC § 112 Claims 3, 4, and 22 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. Claims 4 and 22 recite the word preferably and it is not clear is the preference is intended to be a requirement of the claims. Correction is requested. With regard to claim 3, the M.P.E.P. explains the following: 2173.05(s) Reference to Figures or Tables [R-10.2019]: Where possible, claims are to be complete in themselves. Incorporation by reference to a specific figure or table "is permitted only in exceptional circumstances where there is no practical way to define the invention in words and where it is more concise to incorporate by reference than duplicating a drawing or table into the claim. Incorporation by reference is a necessity doctrine, not for applicant’s convenience." Ex parte Fressola, 27 USPQ2d 1608, 1609 (Bd. Pat. App. & Inter. 1993) (citations omitted). Here, it appears that the XRPD peak data can be provided to practically define the invention without exceptional need to reference Figure 1. Further, the term “substantially” in the context of the claim and Specification is not clear. For example, while the Specification defines this term to include a deviation of 0.1 to 0.2, the claim already includes a limitation of +/-0.2 as it dependent from claim 1. As such, it is not clear if the claim is already inclusive of a substantial deviation or if such is in addition to the margin of error set forth in independent claim 1. With further regard to claim 22, if the preferred embodiments are merely a range it remains improper for being a narrow range within a broader range. Claim Rejections - 35 USC § 112 The following is a quotation of 35 U.S.C. 112(d): (d) REFERENCE IN DEPENDENT FORMS.—Subject to subsection (e), a claim in dependent form shall contain a reference to a claim previously set forth and then specify a further limitation of the subject matter claimed. A claim in dependent form shall be construed to incorporate by reference all the limitations of the claim to which it refers. The following is a quotation of pre-AIA 35 U.S.C. 112, fourth paragraph: Subject to the following paragraph [i.e., the fifth paragraph of pre-AIA 35 U.S.C. 112], a claim in dependent form shall contain a reference to a claim previously set forth and then specify a further limitation of the subject matter claimed. A claim in dependent form shall be construed to incorporate by reference all the limitations of the claim to which it refers. Claims 2, 3, and 21 are rejected under 35 U.S.C. 112(d) or pre-AIA 35 U.S.C. 112, 4th paragraph, as being of improper dependent form for failing to further limit the subject matter of the claim upon which it depends, or for failing to include all the limitations of the claim upon which it depends. In particular claims 2 and 3 are limited to a specific polymorph, which is the same polymorph claimed in instant claim 1. It is not clear how the identical polymorph of claims 2 and 3 further limit the same polymorph of claim 1. The examiner acknowledges that the identical polymorph is described differently, but it would appear that it is not possible to infringe claim 1 without also infringing claims 2 and 3. Further, claim 21 does not appear to be further limiting of claim 1 because it broadens claim 1. Claim 1 is directed to a single compound with nothing else. Conversely, dependent claim 21 is an open-ended composition comprising the compound of claim 1 and anything else. As such, claim 21 does not further limit claim 1. Applicant may cancel the claim(s), amend the claim(s) to place the claim(s) in proper dependent form, rewrite the claim(s) in independent form, or present a sufficient showing that the dependent claim(s) complies with the statutory requirements. Conclusion Any inquiry concerning this communication or earlier communications from the examiner should be directed to JARED D BARSKY whose telephone number is (571)272-2795. The examiner can normally be reached on 9-5 M-F. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Amy Clark can be reached on 571-272-1310. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /JARED BARSKY/Primary Examiner, Art Unit 1628
Read full office action

Prosecution Timeline

Dec 16, 2023
Application Filed
Feb 04, 2026
Non-Final Rejection — §112
Mar 30, 2026
Response Filed

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12576152
TOPICAL COMPOSITION
2y 5m to grant Granted Mar 17, 2026
Patent 12569458
METHOD TO DELIVER ANTIFIBRINOLYTIC DRUGS TO MITIGATE DAMAGE TO THE BRAIN CAUSED BY CONCUSSIVE IMPACT
2y 5m to grant Granted Mar 10, 2026
Patent 12564582
USE OF PRIDOPIDINE FOR TREATING DYSTONIAS
2y 5m to grant Granted Mar 03, 2026
Patent 12558397
COMPOSITION FOR PREVENTION, AMELIORATION, OR TREATMENT OF URINATION-RELATED DISEASES COMPRISING CEPHALOTOCIN
2y 5m to grant Granted Feb 24, 2026
Patent 12558349
METHODS OF TREATING INFECTIONS IN OVERWEIGHT AND OBESE PATIENTS USING ANTIBIOTICS
2y 5m to grant Granted Feb 24, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

AI Strategy Recommendation

Get an AI-powered prosecution strategy using examiner precedents, rejection analysis, and claim mapping.
Powered by AI — typically takes 5-10 seconds

Prosecution Projections

1-2
Expected OA Rounds
50%
Grant Probability
62%
With Interview (+11.5%)
2y 7m
Median Time to Grant
Low
PTA Risk
Based on 915 resolved cases by this examiner. Grant probability derived from career allow rate.

Sign in for Full Analysis

Enter your email to receive a magic link. No password needed.

Free tier: 3 strategy analyses per month